Physician profile
Imad Domat
NPI 1023012457
$15,453.94
in general payments reported to CMS, 2019-2025
42 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $1,563 · 2021: $2,648 · 2022: $2,137 · 2023: $2,604 · 2024: $2,564 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,222 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,222.19 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,257.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $2,070.41 | 2019-2024 | Xarelto |
| Amgen INC. | $1,569.50 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,395.02 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,110.01 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $989.89 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $779.61 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $719.01 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $587.47 | 2019-2025 | Lifevest |
| Pfizer INC. | $560.19 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $486.50 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $380.15 | 2019-2024 | |
| Medtronic, INC. | $270.71 | 2024-2025 | Ffrangio |
| Novo Nordisk INC | $257.74 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Heartflow, INC. | $230.41 | 2023-2025 | Ffrct |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $204.45 | 2022-2025 | Injectafer |
| Boston Scientific Corporation | $202.35 | 2019-2025 | General - Therapies, Synergy, Watchman |
| Cvrx, INC. | $163.18 | 2021-2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $145.88 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $96.79 | 2023 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $88.91 | 2022-2023 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $87.22 | 2022-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $86.20 | 2019-2021 | |
| Abbott Laboratories | $70.17 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $69.64 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $65.66 | 2019-2022 | |
| Bridgebio Pharma, INC. | $65.13 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $61.31 | 2025 | Shingrix, Arexvy |
| Irhythm Technologies, INC. | $52.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $51.90 | 2020 | |
| Cardiva Medical, INC. | $50.65 | 2021-2025 | Cardiva Vascade 6/7f Vcs |
| Esperion Therapeutics, INC. | $39.34 | 2021-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $38.08 | 2019 | |
| Preventice Services, LLC | $25.07 | 2021 | |
| Scpharmaceuticals INC. | $20.54 | 2023 | |
| Teleflex LLC | $19.61 | 2025 | Guardian |
| Tactile Systems Technology INC | $18.20 | 2021 | |
| Philips North America LLC | $17.07 | 2025 | Fleet Management |
| Vifor Pharma, INC. | $16.91 | 2021 | |
| Watermark Medical, INC. | $15.94 | 2025 | |
| Baxter Healthcare | $15.11 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $2.15 | 2024 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Domat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.